EUR 24.8
(4.2%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 35.86 Million EUR | 26.98% |
2022 | 27.17 Million EUR | 41.33% |
2021 | 18.49 Million EUR | 14.88% |
2020 | 14.73 Million EUR | -33.32% |
2019 | 22.83 Million EUR | 25.69% |
2018 | 19.93 Million EUR | 26.77% |
2017 | 15.74 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 8.65 Million EUR | -13.77% |
2024 Q2 | 8.98 Million EUR | 3.8% |
2023 Q2 | 8.62 Million EUR | 18.3% |
2023 Q1 | 7.28 Million EUR | 0.96% |
2023 FY | - EUR | 26.98% |
2023 Q4 | 9.38 Million EUR | -8.35% |
2023 Q3 | 10.23 Million EUR | 18.72% |
2022 Q4 | 7.21 Million EUR | -12.68% |
2022 Q3 | 8.26 Million EUR | 23.98% |
2022 Q2 | 6.66 Million EUR | 35.92% |
2022 Q1 | 4.9 Million EUR | -16.69% |
2022 FY | - EUR | 41.33% |
2021 Q1 | 1.73 Million EUR | 462.66% |
2021 Q4 | 5.88 Million EUR | -10.85% |
2021 Q3 | 6.6 Million EUR | 57.51% |
2021 FY | - EUR | 14.88% |
2021 Q2 | 4.19 Million EUR | 142.01% |
2020 Q2 | 5.32 Million EUR | 20.45% |
2020 FY | - EUR | -33.32% |
2020 Q4 | 308 Thousand EUR | -93.39% |
2020 Q3 | 4.65 Million EUR | -12.51% |
2020 Q1 | 4.42 Million EUR | -45.65% |
2019 Q1 | 3.79 Million EUR | 0.0% |
2019 FY | - EUR | 25.69% |
2019 Q4 | 8.13 Million EUR | 52.14% |
2019 Q3 | 5.34 Million EUR | -1.87% |
2019 Q2 | 5.44 Million EUR | 43.61% |
2018 FY | - EUR | 26.77% |
2017 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
MPH Health Care AG | 33.31 Million EUR | -7.667% |
Apontis Pharma AG | -12.94 Million EUR | 377.159% |
Dermapharm Holding SE | 277.29 Million EUR | 87.065% |
Evotec SE | 7.82 Million EUR | -358.494% |
MERCK Kommanditgesellschaft auf Aktien | 5.52 Billion EUR | 99.35% |
SynBiotic SE | -7.12 Million EUR | 603.58% |